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Patients with chronic daily headache and overuse of analgesics, triptans, or other acute headache compounds, are considered to suffer
frommedication-overuseheadache (MOH).This implies thatmedicationoveruse is the causeofheadache chronification. It remains akey
question why only two-thirds of patients with chronic migraine-like headache and overuse of painmedication improve after detoxifica-
tion, whereas the remainder continue to have chronic headache. In the present longitudinal MRI study, we used voxel-basedmorphom-
etry to investigate graymatter changes related tomedicationwithdrawal in a group of humanswithMOH.As amain result, we found that
only patients with significant clinical improvement showed a significant decrease of previously increased gray matter in the midbrain
including periaqueductal gray matter and nucleus cuneiformis, whereas patients without improvement did not. Patients without treat-
ment response had less gray matter in the orbitofrontal cortex. Another striking result is the correlation of treatment response with the
amount of orbitofrontal graymatter. Thus, we demonstrate adaptive graymatter changes within the painmodulatory system in patients
withMOHwho responded to detoxification, probably reflecting neuronal plasticity. Decreased graymatter in the orbitofrontal cortex at
baseline may be predictive of poor response to treatment.
Introduction
Medication-overuse headache (MOH) is a complication of mi-
graine that causes significant social and financial burden.MOH is
defined as headache for 15 days per month that develops, or
significantly worsens, during medication overuse (Headache
Classification Subcommittee of the International Headache So-
ciety, 2004; Olesen et al., 2006). According to the diagnostic
criteria of the Headache Classification Subcommittee of the In-
ternational Headache Society (2004), MOH could only be diag-
nosed if chronic headache returned to its episodic pattern after
the cessation ofmedication overuse. Thus, the diagnosis ofMOH
could only be made retrospectively. In 2006, a broader definition
of MOH was proposed (Olesen et al., 2006) in which the im-
provement after withdrawal was no longer mandatory, thus al-
lowing for a prospective diagnosis.
Recent studies demonstratedmetabolic and structural abnor-
malities in MOH (Fumal et al., 2006; Riederer et al., 2012). In a
PET study, persistent hypometabolism was found in orbitofron-
tal cortex (OFC), whereas other dysmetabolic regions returned to
normal after withdrawal (Fumal et al., 2006). Since hypofunction
of the OFC is known to occur in drug dependence, it was sug-
gested that this may predispose subgroups of persons who expe-
rience migraine headaches to recurrent medication overuse
(Fumal et al., 2006). Voxel-basedmorphometry (VBM) is a pow-
erful tool with which to study neurological disease, with the
detection of structural changes in the brain being operator inde-
pendent (Ashburner and Friston, 2000; Whitwell, 2009). In a
VBM study, we found gray matter (GM) changes in structures
related to pain processing and antinociception (Riederer et al.,
2012). Specifically, GM increases were found in the periaqueduc-
tal gray of the midbrain (PAG), the thalamus, and the striatum,
and decreases were found in frontal regions, including OFC and
the insula.
The PAG is a substantial component of the descending pain
modulatory network and exerts an inhibitory or excitatory
control on nociceptive transmission via the rostral ventrome-
dial medulla (RVM), which in turn projects to the spinal and
medullary dorsal horn (Heinricher et al., 2009; Benarroch,
2012). While it is widely accepted that that the brainstem plays
a pivotal role in migraine pathophysiology (Raskin et al., 1987;
Weiller et al., 1995; Veloso et al., 1998; Welch et al., 2001;
Afridi et al., 2005), dysfunction of descending pain modula-
tory systems with a shift toward pain facilitation has recently
been suggested in MOH (Perrotta et al., 2010, 2012). Impor-
tantly, abnormal processing of pain stimuli and impaired su-
Received Aug. 9, 2012; revised July 11, 2013; accepted July 12, 2013.
Author contributions: F.R. and P.S.S. designed research; F.R., A.R.G., M.M., and R.L. performed research; R.L. and
S.K. contributed unpublished reagents/analytic tools; F.R. and M.M. analyzed data; F.R., S.K., and P.S.S. wrote the
paper.
Thisworkwas supportedby theWerner Alfred Selo Stiftung and the SchweizerischeNationalfonds zur Fo¨rderung
der Wissenschaftlichen Forschung, project no. 3200030_127606/1 (P.S.S.).
The authors declare no competing financial interests.
Correspondence should be addressed to Peter S. Sa´ndor, Rehaclinic Bad Zurzach, Quellenstrasse 34, CH-5330Bad
Zurzach, Switzerland. E-mail: peter.sandor@ksb.ch.
DOI:10.1523/JNEUROSCI.3804-12.2013
Copyright © 2013 the authors 0270-6474/13/3315343-07$15.00/0
The Journal of Neuroscience, September 25, 2013 • 33(39):15343–15349 • 15343
praspinal pain control in patients with MOH improved after
detoxification.
Here we investigated whether the GMchanges associated with
MOH inhumans, such as increase in themidbrain, thalamus, and
striatum, and decrease in frontal regions (Riederer et al., 2012),
were reversible after detoxification. Assuming that VBM detects
neuroplasticity in adults (Draganski et al., 2004; May, 2011), we
hypothesized neuroplastic changes particularly in brainstem and
frontal cortex in patients with significant clinical improvement
(responders), but not in the patients without improvement
(nonresponders).
Further, we investigated whether regional GM changes at
baseline would distinguish between responders and nonre-
sponders, and thus predict treatment response, focusing onOFC.
To test these hypotheses, high-resolution structural MRIs were
performed in MOH patients before and after detoxification.
Materials andMethods
This is an extension of a previously published study (Riederer et al.,
2012). The study was approved by the ethics committee of the Canton
Zurich. Written informed consent was obtained from all study partici-
pants according to the Declaration of Helsinki.
Subjects. Thirty-eight patients with MOH, according to the proposed
revision of criteria of the Headache Classification Subcommittee of the
International Headache Society (2004) by Olesen (Olesen et al., 2006),
were included in the study.Medication overuse was defined as treatment
with the following acute/symptomatic treatment drugs: ergotamine,
triptans, opioids, or combination analgesic medications 10 d/month;
or simple analgesics or any combination of ergotamine, triptans, or an-
algesics opioids without overuse of any single class alone 15 d/month
(Headache Classification Subcommittee of the International Headache
Society, 2004; Olesen et al., 2006) on a regular basis for3 months.
Headache days per month and days with pain medication per month
were recorded during a baseline period at least 1month before scan 1 and
in the month before scan 2, which was scheduled at least 3 months after
scan 1, based onheadache diaries. Patientswere considered as responders
if they had a reduction of50% in headache days per month at follow-
up. Each responder was age and gender matched to a corresponding
nonresponder. Patients with known abnormalities in brain imaging
(MRI or CT scans) were not included.
Structural MRI. High-resolution structural MRI was performed in all
patients before medication withdrawal and 3 months after. All MRI data
were obtained on a 3 tesla Philips Achieva scanner (Philips Medical Sys-
tems) at the Institute for Biomedical Engineering, Swiss Federal Institute
of Technology and University of Zurich. The T1-weighted volume se-
quences of the whole brain were acquired using a three-dimensional
magnetization-prepared rapid acquisition gradient echo sequence (TR,
8.7ms; TE, 2.3ms; flip angle, 8.0°; voxel size, 0.86 0.86 1.0mm; axial
slice orientation, matrix size 256 256).
Voxel-based morphometry. Images were analyzed with the VBM8 tool-
box (http://dbm.neuro.uni-jena.de/vbm/), incorporated in the SPM8
software running on MATLAB R2008b (MathWorks). The longitudinal
preprocessing approach integrated into the VBM8 toolbox was used
(Bezzola et al., 2011). In brief, the following steps were performed: (1)
registration of time point 2 scan to time point 1 scan for each subject
separately; (2) intrasubject bias correction; (3) segmentation into differ-
ent tissue classes; (4) linear and nonlinear registration; and (5) modula-
tion of tissue segments by the nonlinear normalization parameters to
account for individual brain size differences. The normalized GM seg-
ments were smoothed using a 6 mm FWHMGaussian kernel.
Statistical analysis. Clinical data were analyzed with IBM SPSS Statis-
tics 20 program. Student’s t tests were used to compare parametric data
and Mann–Whitney U tests for nonparametric data.
Imaging data were analyzed with SPM8 (http://www.fil.ion.ucl.ac.
uk/spm/software/spm8/). First, baseline and follow-up scans were com-
pared in responders and nonresponders matched for age and sex, using a
repeated-measures ANOVA (flexible-factorial) model with within-
subject factor time (T1, T2) andbetween-subjects factor group (respond-
ers, nonresponders), testing for a group time interaction. T-contrasts
were defined to identify regions with significant GMdecrease or increase
from scan 1 to scan 2 in responders and nonresponders, respectively. The
resulting set of voxels for each contrast was thresholded at p  0.05,
corrected for multiple comparisons with familywise error. For pre-
defined regions (midbrain, thalamus, insula, striatum, OFC, and pre-
frontal cortex), a region of interest (ROI) analysis was performed, using
WFU-PickAtlas (at p 0.05, corrected).
Subsequently, baseline scans of responders and matched nonre-
sponders were compared using a two-sample t test model. Total GM
volume was used as nuisance variable. Here, SPM small-volume correc-
tion (sphere with a radius of 10 mm, at p 0.05) within the predefined
ROIs was used. For all analyses, an extent threshold of a minimum of 5
voxels was used. All coordinates are given in Montreal Neurological In-
stitute (MNI) space. In the significant cluster in the OFC cortex that
resulted from baseline comparisons, individual GM volumes of all pa-
tients were extracted using the marsbar toolbox and correlated with
treatment response (defined as the percentage reduction in headache
days at follow-up) within SPSS.
Possible correlation of cerebral GM at baseline with intake of acute
medication (days with pain medication per month) were investigated in
a multiple regression model within SPM8, including total GM volume,
age, and gender as nuisance variables. Whole-brain and ROI analyses
using WFU-PickAtlas (at p 0.05, corrected) were performed.
Results
Clinical data
Four patients were lost during follow-up, and three patients (two
classified as responders, one as a nonresponder) refused to un-
dergo the secondMRI scan. Complete clinical and imaging data-
sets could be obtained from 31 patients (17 responders, 14
nonresponders). Results from this group were similar to those in
the present study and have been published in abstract form (Rie-
derer et al., 2013). Eleven responders (9 females, 2 males) could
be age and gender matched to 11 nonresponders (9 females, 2
males). Demographic and clinical data of this group are summa-
rized in Table 1. Baseline characteristics did not differ signifi-
cantly between responders and nonresponders. At follow-up,
responders had significantly more reduction in number of head-
ache days and significantly fewer days on pain medication than
nonresponders. Most patients overused triptans and/or simple
analgesics. All medications, including prophylactic medications,
are listed in Table 2.
Follow-up 12months after detoxification
Electronic charts were available from all patients. Twelvemonths
after detoxification data were available for 10 responders and 8
Table 1. Demographic and clinical data in patients with MOH
Responders
(N 11)
Nonresponders
(N 11) p valuea
Time between scans (d) 113.2 42.6 107.3 32.3 0.720 (t test)
Age (years) 41.8 9.1 44.3 12.0 0.365
Gender (female/male) 9/2 9/2 NA
Headache
d/month at baseline 25.0 6.8 26.2 5.3 0.652
% reduction 73.4 10.1 18.7 27.5 0.001
Receiving medication
d/month at follow-up 6.4 4.9 12.8 9.4 0.047
d/month at follow-up 14.2 8.7 10.4 10.8 0.300
Headache duration (years) 20.1 12.2 19.0 10.0 1.000
HADS-A (baseline) 8.5 4.2 8.3 3.6 0.898
HADS-D (baseline) 7.9 6.3 6.9 5.0 0.699
HADS, Hospital Anxiety and Depression Scale; HADS-A, anxiety subscale; HADS-D, depression subscale; NA, not
applicable.
aMann–Whitney U test, unless otherwise indicated.
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nonresponders. Two responders had relapsed to MOH after 12
months. Nonresponders continued to have chronic headaches.
Imaging data
In responders, GM in the midbrain (x5, y34, z8;
T  6.12, p  0.006, ROI corrected; cluster size, k  21 voxels)
decreased significantly after medication withdrawal (Fig. 1). In
contrast, in nonresponders theGMbetween scans 1 and 2was not
significantly different. In all patients, GM in the significant mid-
brain cluster (Fig. 1) was extracted for scans 1 and 2. The differ-
ence in extracted GM between scans 1 and 2 correlated positively
with treatment response (Spearman’s  0.500, p 0.018; cor-
rected for age:   0.551, p  0.010; i.e., greater GM reduction
was associated with greater treatment response). The difference
in extracted GM in the midbrain did not correlate with the re-
duction of days per month with acute medication intake (Spear-
man’s  0.161, p 0.473). No other regions showed significant
GM decreases in responders and nonresponders.
Then, we defined T-contrasts to identify regions where GM
would increase significantly from scan 1 to scan 2. No significant
clusters were identified in responders or nonresponders.
Subsequently, we defined T-contrasts to identify GM in-
creases or decreases between responders and nonresponders at
baseline. Nonresponders had significantly less GM in the right
OFC (x 8, y 32, z26; T 5.43, p 0.012, SVC corrected;
cluster size, k  26 voxels). Extracted GM in this cluster corre-
lated positively with treatment response (Spearman’s  0.687,
p 0.001; Fig. 2). This correlation persisted when corrected for
age (Spearman’s  0.618, p 0.003).
No significant correlation between GM at baseline and days
with pain medication per month were found.
Discussion
In this study, we investigated whether GM changes related to
MOH such as increased GM in the midbrain and decreased GM
in frontal regions are reversible after detoxification. The main
findingwas that GM in themidbrain, which had been found to be
increased compared with healthy controls in a previous study
(Riederer et al., 2012), significantly decreased only in patients
who responded to treatment (i.e., those who had at least a 50%
reduction in number of headache days). Nonresponders showed
no significant changes between scans 1 and 2. The magnitude of
GM reduction correlated positively with treatment response. In
addition, we found that nonresponders had less GM in the OFC
at baseline and a positive correlation of GM in this region with
response to treatment (i.e., more GM at baseline was associated
with a greater reduction of headache days at follow-up).
We suggest that a decrease of GM in the midbrain may indi-
cate neuronal plasticity related to restitution of a facilitatory/
inhibitory balance within the descending pain-modulating
systems.
Brainstem dysfunction has been suggested in migraine (Pi-
etrobon and Striessnig, 2003). It has been observed that electrical
stimulation for pain other than headache (Raskin et al., 1987;
Veloso et al., 1998) or lesions in the PAG (Haas et al., 1993;
Goadsby, 2002) can cause migraine-like headaches in previously
migraine-free subjects. Structural abnormalities include in-
creased GM inmigraine (Rocca et al., 2006) and progressive per-
turbation of iron homeostasis in episodic and chronic migraine
(Welch et al., 2001). Functional neuroimaging studies reported
increased metabolism in the brainstem during spontaneous mi-
graine attacks (Weiller et al., 1995; Afridi et al., 2005). Areas of
increased metabolism probably included the dorsal raphe nu-
cleus (DRN) located ventrally to the PAG and the locus ceruleus
(Weiller et al., 1995).
Based on Duvernoy’s Atlas of the Human Brain Stem and Cer-
ebellum (Naidich et al., 2009), the longitudinal GM decreases
observed in our study included the PAG, adjacent midbrain re-
ticular formationwith nucleus cuneiformis (NCF), and theDRN.
The PAG has a major role in integrated behavioral responses
of an individual to pain or external stimuli such as threat, coor-
dinating specific patterns of cardiovascular, motor, and pain
modulatory responses, according to the type of stress and the
individuals perception to support active (e.g., fight or flight) or
passive coping strategies (Benarroch, 2012). The PAG consists of
Table 2. Medication in patients withmedication-overuse headache
Patient No. Responder Sex Age (years)
Prophylactic medications
Acute headache medication ContraceptivesMRI 1 MRI 2
1 Yes M 43 Topiramate, duloxetine Duloxetine Triptans, SA —
2 Yes F 46 Pregabalin, trimipramine, venlafaxine Pregabalin, trimipramine, venlafaxine SA —
3 Yes F 26 — Magnesium, riboflavin SA IUD (gestagen)
4 Yes F 23 Magnesium, riboflavin, topiramate, blockers — Triptans, SA —
5 Yes F 41 Valproate, magnesium Riboflavin, candesartan Triptans, SA —
6 Yes F 42 Lamotrigine Topiramate Triptans, CA —
7 Yes M 50 Venlafaxine Venlafaxine, lamotrigine, trazodone Triptans, SA —
8 Yes F 46 — Venlafaxine Triptans Oral contraceptive
9 Yes F 48 — — Triptans —
10 Yes F 51 Magnesium Magnesium, metoprolol SA —
11 Yes F 44 — Valproate Triptans —
12 No M 50 Valproate, mirtazapine, riboflavin Trazodone, duloxetine Triptans, SA —
13 No F 42 Magnesium Metoprolol Triptans, SA Vaginal ring
14 No F 23 — Venlafaxine, riboflavin, magnesium SA Oral contraceptive
15 No F 53 — — Triptans .-
16 No F 45 Riboflavin, magnesium Venlafaxine, magnesium Triptans —
17 No F 56 — Topiramate Triptans, SA —
18 No F 45 Topiramate Topiramate SA —
19 No F 54 Magnesium, riboflavin, pregabalin — Triptans —
20 No F 21 Magnesium Topiramate SA —
21 No M 44 Citalopram Riboflavin SA, triptans —
22 No F 54 Mirtazapin Mirtazapin, venlafaxine, magnesium SA —
CA, Combination analgesics; IUD, intrauterine device; SA, simple analgesics; M, male; F, female.
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distinct longitudinal columns that receive selective afferents from
the forebrain including, OFC regions, brainstem, and sensory
neurons from the dorsal horn and trigeminal nuclei (Behbehani,
1995; Benarroch, 2012). It is a substantial component of the de-
scending pain-modulatory network and exerts an inhibitory or
excitatory control on nociceptive transmission via the RVM,
which in turn projects to the spinal and medullary dorsal horns
(Heinricher et al., 2009).
The NCF is located in the midbrain reticular formation and
has been related to the descending pain-modulating systems, act-
ing in concert with the PAG (Dunckley et al., 2005). It is recipro-
cally connected with the PAG, receives input from forebrain
regions including amygdala and hypothalamus, and projects to
the RVM (Mantyh, 1983; Zemlan and Behbehani, 1988; Bernard
et al., 1989; Hadjipavlou et al., 2006). The NCF is activated by
nociceptive stimuli and has been implicated in central sensitiza-
tion in fMRI studies (Dunckley et al., 2005; Zambreanu et al.,
2005). The NCF was found hypofunctional in individuals expe-
riencingmigraines (Moulton et al., 2008). TheNCF, like the PAG
and RVM, contains functionally distinct classes of neurons that
can enhance nociception (“ON cells”) or inhibit nociception
(“OFF cells”) (Fields et al., 1983; Heinricher et al., 1987; Haws et
al., 1989).
Decreased descending inhibition or increased facilitation to
the medullary dorsal horn, with increased sensitization and con-
sequently increased nociception from dural and meningeal vas-
cular afferents, has been suggested to be involved in the
development of chronic daily headache (Okada-Ogawa et al.,
2009). Consistently, patients with active MOH have increased
pain perception and nociceptive withdrawal reflex in cephalic
and extracephalic regions, which normalize after detoxification
(Perrotta et al., 2010, 2012; Munksgaard et al., 2012). Possible
mechanisms probably include sensitization in trigeminal ganglia
and medullary dorsal horn induced by triptans or opiates
(Okada-Ogawa et al., 2009; De Felice et al., 2010).
In our data, GM changes also included the DRN, a major
source of widespread serotonergic projections to the forebrain
(Michelsen et al., 2007). Alterations in serotonergic transmission
Figure 1. A, Voxels with significant GM decrease in responders after detoxification projected on anMRI of a patient withMOH. Voxels include the PAG andmidbrain reticular formation (RF). The
right side in the coronal section and the lower side in the axial section correspond to the right patient side. For display, results were thresholded at p 0.001, uncorrected. Slice locations are given
inMNI space.B, Plots of effect size (parameter estimates in centered arbitrary units, 90%CI) fromSPManalyses in theglobalmaximum. The x-axis indicates timepoints ofMRI scans for responders
(T1, beforedetoxification; T2, after detoxification).Only responders showasignificantGMdecrease in themidbrain fromscan1 to scan2 [repeated-measuresANOVA,p0.05, corrected formultiple
comparisons with familywise error (FWE) across the ROI]. Exploratory analyses showed that responders hadmore GM in themidbrain at baseline comparedwith nonresponders (two-sample t test,
p 0.005, uncorrected). C, GM volumes in the significant cluster from A extracted from individual scans. **p 0.001, paired t test. D, The magnitude of gray matter volume reduction correlates
with reduction in the number of headache days per month in percentage from baseline (Spearman’s  0.500, p 0.018).
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havebeen reported inmodelsofMOH, includinganupregulationof
5-HT2A receptors in cortical projection areas (Supornsilpchai et al.,
2010; Bongsebandhu-phubhakdi and Srikiatkhachorn, 2012).
Triptans are selective 5-HT1B/D receptor agonists, binding also in the
PAG, where they influence nociception, possibly via serotonergic
mechanisms (Bartsch et al., 2004; Lambert, 2005). Chronic triptan
administration decreased 5-HT1B/D receptor mRNA in the trigemi-
nal ganglionandthebasilar artery (Reuter et al., 2004), and increased
the rate of 5-HTsynthesis inprojection areas, probably related to the
downregulation of inhibitory 5-HT1 autoreceptors (Dobson et al.,
2004). Similarly, a downregulation of 5-HT1B/D receptors and an
increased 5-HT synthesis could be assumed in themidbrain. In our
data, no significant correlation betweenGMdecrease and reduction
of medication intake, or GM at baseline andmedication intake was
found.
Due to methodological limitations, a precise mechanism can-
not be delineated since the histopathological correlates of GM
changes are not yet fully understood. Whereas it seems evident
that neuronal loss and gliosis is associated with GM decreases
(Riederer et al., 2008), the reverse cannot be concluded, since
reversible GM decreases have been observed in pain syndromes
(Rodriguez-Raecke et al., 2009). Stimulus-dependent GM in-
creases have been demonstrated in learning tasks (Draganski et
al., 2004) and repetitive painful stimuli (Teutsch et al., 2008). GM
changes have been related to neuronal or glial cell genesis or
degeneration; increases/decreases in cell size, spine, or synapse
turnover; or changes in blood flow or interstitial fluids (May,
2011), and may reflect a combination of these.
In our data, nonresponders had less GM in the right OFC at
baseline, and a positive correlation between GM and treatment
response was found. Formally, these patients are to be diagnosed
as chronic migraine according to Headache Classification Sub-
committee of the International Headache Society (2004) criteria.
Metabolic and functional changes within theOFC have been pre-
viously suggested in MOH. In a PET study, all regions that have
been shown to be dysmetabolic in active MOH returned to nor-
mal after detoxification, except for the OFC, where hypometab-
olism persisted (Fumal et al., 2006). Neuropsychological studies
have shown that poor performance in tasks related to OFC func-
tion in MOH patients predicts poor outcome after withdrawal
(Go´mez-Beldarrain et al., 2011). Dysfunction of OFC, particu-
larly on the right side, has been implicated in maladaptive deci-
sion making, and dysfunction of OFC has been related to drug
addiction (Tranel et al., 2002; Tanabe et al., 2009; Lucantonio et
al., 2012). Patients with MOH fulfill certain criteria of substance
dependence, with its severity being predictive for the outcome
after detoxification (Fuh et al., 2005; Radat et al., 2008; Lundqvist
et al., 2012). OFC dysfunction might thus interfere with internal
control to repeated medication intake; in addition, OFC projec-
tions to the PAG may influence its pain modulation.
While there are several cross-sectional morphometric studies
on headache (May, 2009), there are only few VBM studies inves-
tigating potentially reversible pain syndromes longitudinally.
Obermann et al. (2009) found a GM decrease in the dorsolateral
prefrontal cortex and in the anterior cingulate cortex in pa-
tients who developed chronic post-traumatic headache. In the
follow-up investigation, after 12 months, when patients had be-
come pain free, GM decreases were found to be reversible. In
addition, an increase in GM was found after 12 months in the
thalamus and in the midbrain, suggesting an association with
antinociceptive mechanisms.
Two other studies investigated GM changes associated with
osteoarthritis of the hip before and after surgery (Rodriguez-
Raecke et al., 2009; Gwilym et al., 2010). Both studies reported
reversible GM changes. The first study (Rodriguez-Raecke et al.,
2009) reported GM increases in the dorsolateral prefrontal cor-
tex, anterior cingulate cortex, and brainstem, whereas the other
study (Gwilym et al., 2010) found reversible GM atrophy in the
thalami. All aforementionedVBM studies reportedGM increases
within a time period of 4–12 months.
In our study, we did not find any GM increases in frontal,
especially OFC, regions, possibly because patient samples and
observation periods differed, whichwas against our expectations.
Also, changes in GMwithin structures of the reward system, such
as the ventral striatum, and changes in the thalamus did not
reverse after detoxification.
Figure2. A, Responders have significantlymore graymatter volume thannonresponders at baseline in the orbitofrontal cortex. R indicates right.B, Extracted graymatter in this region correlates
positively with relative reduction in number of headache days per month (Spearman’s 0.687, p 0.001; i.e., more gray matter volume at baseline was associated with a greater reduction of
headache days at follow-up). The x-axis indicates the reduction of number of days with headache permonth in percentage from baseline. The y-axis indicates graymatter volume in arbitrary units.
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A limitation of this study might be that possible influences of
prophylacticmedication or a combination ofmedications cannot
be ruled out entirely. However, most patients were on prophy-
lactic medication before and after detoxification. Antidepres-
sants and anticonvulsants seem generally not to be associated
with volumetric differences, according to a recent review (Hafe-
man et al., 2012).
Conclusions
Our data show that response to the withdrawal of acute headache
medication is associatedwith the decrease of previously increased
GM in the midbrain. The lack of longitudinal GM changes in
other regions (e.g., the ventral striatum and OFC) might under-
pin the idea that these patients are prone to relapse and deserve
dedicated care, including multimodal treatment strategies. Fu-
ture studies should investigate correlations of GM changes with
behavioral measures assessing dependence and impulse control.
Animalmodels ofmedication-induced sensitization should focus
on midbrain structures such as the PAG and NCF.
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